|
Kanglaite Injection Phase I Study Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Kanglaite Injection Phase I Study conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Kanglaite Injection Phase I Study Clinical research trials and Kanglaite Injection Phase I Study health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Kanglaite Injection Phase I Study. Kanglaite Injection Phase I Study Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Kanglaite Injection Phase I Study clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Kanglaite Injection Phase I Study condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "K" Clinical Trials Conditions > Kanglaite Injection Phase I Study Kanglaite Injection Phase I Study
Kanglaite Injection Phase I Study
For Condition: Solid Tumors Refractory To Standard Therapy,Neoplasms
Status: Recruiting
Sponsor(s): Kanglaite-USA ,
Synopsis: The Kanglaite Injection (KLT)is a novel broad spectrum anti-cancer injection produced from traditional Chinese medicinal herbs (the Coix Seed). It was approved in China in 1995 and has become the most popular anti-cancer drug in China. In June of 2001, the Phase I study of KLT commenced at the Huntsman Cancer Institute in Salt Lake City, Utah, with the objectives of 1) To determine the maximum tolerated dose (MTD) and the safety profile of KLT in patients with refractory solid tumors; 2) To determine the pharmacokinetics of KLT in patients with refractory solid tumors; and 3) To gather preliminary efficacy data. The method of testing is open-label, sequential cohort, dose-escalation study.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Patients with histological evidence of malignancy that has become refractory to standard therapy, or for whom effective standard therapy does not exist. - Patients with an estimated life-expectancy of at least 3 months - Patients with a Karnofsky Performance Score of at least 60% - Patients with no history of congestive heart failure (CHF), and normal ejection fraction by echocardiography - Patients with adequate renal and hepatic function - Patients with adequate bone marrow status
Total Enrollment: 18
Location and Contact Information:
Overall Study Official:
RichardWheeler, Principal Investigator, Huntsman Cancer Institute
Huntsman Cancer Institue *Recruiting*
Salt Lake City, Utah, 84112
United States
Recruiting Rita Gerard 801-585-0550
Additional Information:
Study ID Numbers: KN-001-01;
Study Start Date: June 2001
Record last reviewed: March 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00031031
Other Solid Tumors Refractory To Standard Therapy Studies:
1. Phase I Study of Anakinra to Treat Advanced Cancers that Produce Interluekin-1
2. Cancer Pain
3. Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
4. Endolymphatic Sac Tumors in a Population of Patients with von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients with Early Stage Endolymphatic Sac Tumors
5. D-MPH in the treatment of fatigue and neurobehavioral function related to chemotherapy in adult cancer patients
Related Studies:
Other Solid Tumors Refractory To Standard Therapy Clinical Trials
Other Utah Clinical Trials
Other Salt Lake City Clinical Trials
Kanglaite Injection Phase I Study
|
|
|
|
|
|
|
|